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Abstract
Hereditary angioedema (C1 inhibitor deficiency, HAE) is associated with intermittent swellings which are disabling
and may be fatal. Effective treatments are available and these are most useful when given early in the course of
the swelling. The requirement to attend a medical facility for parenteral treatment results in delays. Home therapy
offers the possibility of earlier treatment and better symptom control, enabling patients to live more healthy, pro-
ductive lives. This paper examines the evidence for patient-controlled home treatment of acute attacks (’self or
assisted administration’) and suggests a framework for patients and physicians interested in participating in home
or self-administration programmes. It represents the opinion of the authors who have a wide range of expert
experience in the management of HAE.
Introduction
Hereditary angioedema (HAE) is an autosomal domi-
nant condition caused by a partial deficiency of C1 inhi-
bitor (C1INH). C1INH controls a variety of local
inflammatory pathways. Insufficient regulation of the
classical complement pathway causes consumption of
the complement component C4, resulting in typical
diagnostic abnormalities. Insufficient inhibition of kallik-
rein results in overproduction of bradykinin, and episo-
dic swelling from excess local bradykinin[1]. Swellings
are typically of slow onset over several hours and last
1-5 days, although some patients may also experience
rapid onset swellings[2]. Almost any part of the body
may be affected, although the subcutaneous and submu-
cosal structures of limbs, genitals, face, mouth and
bowel are the usual sites of swelling. Swellings are
referred to as acute attacks and are interspersed by
asymptomatic periods of days, weeks or months[3-5].
Attacks are associated with reversible disability.
Abdominal attacks are associated with the extreme pain
of bowel obstruction or visceral swelling, and with
vomiting or diarrhoea[3,6]. Patients are typically unable
to undertake their daily activities of living for one or
more days, and may be less productive for a few days
subsequent to attack because of residual angioedema
and fatigue. Peripheral swellings may prevent wearing of
shoes, operation of machinery or may cause disfigure-
ment, thus interfering with work or other activities[7].
Laryngeal swellings comprise a small minority (around
2%) of attacks but may cause death from airway
obstruction[2]. Although for most patients laryngeal
attacks are infrequent and the case fatality of each attack
is low, there is a significant lifetime mortality[3,8]. Fear
of laryngeal attacks and the need for access to lifesaving,
specialist emergency treatment confers considerable
restrictions on patients and their families. In particular,
travel for work or pleasure is often curtailed. Attacks
are more likely to occur at times of emotional stress,
and therefore are more likely to occur during examina-
tions or busy periods at work. Thus, those affected by
HAE and their families are subject to employment and
educational disadvantage[9-11].
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Treatment options
The frequency and severity of attacks is reduced by oral
prophylaxis with attenuated androgens or tranexamic
acid, or by regular intravenous infusion of C1INH con-
centrate[12-14]. However, prophylaxis does not comple-
tely abolish attacks[14]. Moreover, many patients cannot
benefit from oral prophylaxis because of contraindica-
tions, side effects, or lack of efficacy[13,15,16]. Immedi-
ate access to effective acute treatment is therefore
required for all patients.
Replacement therapy with plasma-derived C1INH
(pdC1INH) is effective and has been used successfully
for over 25 years to attenuate or prevent attacks at all
sites [17-19]. More recently, icatibant, a bradykinin
receptor inhibitor, and ecallantide, a kallikrein inhibitor,
have been shown to be effective at treating attacks
[20,21]. Icatibant was licensed for acute angioedema
attacks in patients with C1-inhibitor deficiency in the
European Union and several other countries in 2008.
Ecallantide was licensed for acute attacks in the USA in
2009. After treatment with either icatibant, ecallantide
or C1INH, onset of relief can be expected within 30 to
60 minutes, with full resolution taking a few hours to
longer than 24 hours in established attacks[14,17,20-23].
Observational studies demonstrate faster relief and
reduced attack severity when C1INH is given early
[6,24]. Similarly, icatibant or ecallantide may be more
effective when given early, although this is yet to be
demonstrated in clinical studies.
The requirement to travel to a medical facility for
acute treatment implies at least half a day away from
home, school, or work. In the emergency room setting,
patients with HAE attacks may not be prioritised over
competing emergencies such as patients with heart
attacks, stroke or severe injury. This leads to further
delay, with increased risk of treatment failure and longer
recovery times. Health care staff, unfamiliar with HAE,
are reluctant to treat early, when signs are mild or
absent, contributing further to the delay and disability.
Owing to the reversibility of most attacks, patients
themselves may choose to stay at home with sympto-
matic treatment rather than struggle with access to ther-
apy in the emergency room. This increases absenteeism
from work, school, or home responsibilities. For laryn-
geal attacks, such delay may be fatal. Even where acute
treatment is available, it is estimated that only 5-25% of
attacks receive definitive treatment (Cicardi, personal
communication). Home infusion programmes have been
established in centres with an interest in HAE, and have
the potential to overcome many of the difficulties asso-
ciated with health care facility-based treatment[25-28].
Experience shows that access to self or assisted infu-
sion with C1INH reduces severity and duration of
attacks, improves HAE-related quality of life, reduces
time off work, education or domestic duties, is safe, and
is very popular with participants[23-30]. Self infusion is
endorsed by the UK, Danish and Canadian-Hungarian
consensuses[25,31-34]. Neither UK nor the Canadian
Consensus documents place restrictions on entry to the
programme, other than to note that the diagnosis of
HAE should be proven, prophylactic therapy optimised
(UK document) and that an ‘infusion partner’ (UK) or
‘instruction and support’ (Canadian- Hungarian) should
be available[27,31-34]. The Danish home therapy pro-
gramme considers patients who have more than one
moderate or severe attack every 4 weeks, although in
practice, these restrictions are relaxed where necessary
[25,27].
The C1 inhibitor deficiency workshop was first held in
1999 in Vizegrád, Hungary and has been a biennial
Hungarian event since then. It brings together patients,
physicians, nurses, basic and clinical scientists, blood
product suppliers and representatives of the pharmaceu-
tical industry with a common interest in HAE and its
management. Similarly, the Canadian Hereditary
Angioedema Network (CHAEN)/Réseau d’angioedème
héréditaire du Canada (RAHC) has organised confer-
ences in 2003, 2006 and 2010, with the aim of develop-
ing and updating consensus recommendations for HAE
management http://www.haecanada.com. These work-
shops are attended by experts from all over the world
and represent an unprecedented opportunity to pool
experience and to share information, with the aim of
improving the physical, psychological and economic
wellbeing of those affected by HAE. This article sum-
marises consensus opinion, resulting from debates at the
Hungarian C1 Inhibitor 2009 Workshop and the Cana-
dian Hereditary Angioedema Network (CHAEN)/Réseau
d’angioedème héréditaire du Canada (RAHC) consensus
meeting held in Toronto in May 2010 (Appendix 1).
Home therapy/self-administration in this article,
refers to treatment given in a non-health care set-
ting; given by the patient, a trained relative or friend,
outside of a healthcare facility.
Methods
Participants at the 6th C1 Inhibitor Deficiency Work-
shop, held in Budapest in May 2009, were invited to a
moderated discussion with the aim of forming a consen-
sus approach to home therapy for patients with HAE.
Published literature was found using a PubMed search,
with the terms “C1 inhibitor” or “hereditary angioe-
dema” and “home therapy” or “self-infusion”. Additional
data were found from references in the papers found in
the search and from abstracts known to the authors, not
listed in PubMed. These data were summarised by HL
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and presented as a basis for further discussion. The dis-
cussion was chaired by a physician/immunologist (HL)
and moderated by a representative of the US patients’
association (JL), adult and paediatric physicians, and
physician scientists (TC, WK, BZ). The consensus docu-
ment summarising discussions was drafted by HL and
the facilitators (TC, WK, BZ). This draft was used as a
basis for debate and modification at the Canadian
Toronto May 2010 Consensus Meeting. To date, most
self-administration treatment has been limited to
plasma-derived C1INH (pdC1INH) replacement but is
expected to involve other agents as they become avail-
able (icatibant, recombinant C1INH, other therapies as
they become licensed and available).
Recommendations
1. Inclusions/exclusions
Recommendation: Every patient with HAE should be
considered for home therapy and self-administration
training, once the diagnosis of C1INH deficiency (her-
editary or acquired angioedema) is confirmed.
Prophylaxis should be optimised, but home therapy
need not be delayed since training can take place
alongside other treatments. Attacks occur despite pro-
phylaxis in most patients. Requirement to attend a
medical facility inevitably results in delayed treatment,
and many attacks are not treated at all. This contri-
butes to the social and economic disadvantage asso-
ciated with HAE. For this reason, eligibility for home
therapy should be inclusive. It is strongly recom-
mended that patients train with an ‘home therapy part-
ner ’ (a family member or friend who can provide
support, advice and may additionally be trained to per-
form the therapy administration).
Special situations
(i) Extremes of age;
1. Children: C1INH home therapy is recommended
for children with frequent or disruptive attacks, where a
responsible adult is available and willing to undertake
training. Experience with haemophilia suggests that it is
beneficial for children to be encouraged to take an
active part in their treatment with a view to indepen-
dent administration in their early teens [35].
Comment: Prepubertal children typically experience
fewer attacks than adolescents and adults. However,
some have frequent attacks which disrupt education and
family life[36,37]. Prophylaxis with attenuated androgens
is not recommended, and tranexamic acid may be of
limited benefit[13]. pdC1INH is effective for treatment
of children and home therapy has been used successfully
in this age group (W Kreutz; personal communication).
Icatibant has not been tested in children under 18 years
and is not yet recommended for this age group.
2. Elderly: Advanced age is not a contraindication to
home therapy, providing patient and home therapy part-
ner can function safely and effectively.
(ii) Pregnancy and breastfeeding: pdC1INH home
therapy appears safe and effective and is recommended
for pregnant and lactating women[28,32,38].
Comment: Attack frequency increases in the first tri-
mester of pregnancy for approximately 38% [36] of
women. Prophylaxis with attenuated androgens or tra-
nexamic acid is not recommended in pregnancy. Home
or self-administration should be considered for control
of symptoms for pregnant and lactating women.
Women with HAE contemplating pregnancy should
consider home self-administration training.
(iii) Lack of home therapy partner: While presence
of a trained ‘home therapy partner’ is highly desirable,
lack of a partner does not exclude the possibility of self-
administration, if a risk-benefit assessment is favourable
Comment: Those without an infusion partner may
include students and patients undertaking travel for
work purposes. Patients living alone may experience
particular difficulty in travelling to hospital, and there-
fore may be more likely to present late or to leave
severe attacks untreated if unable to self-administer.
These groups are likely to gain the greatest benefit from
the ability to prevent and control attacks. We recom-
mend that extra care is taken with arrangements for
access to medical back-up where an infusion partner is
not available. Subcutaneous agents such as icatibant
could be considered as an alternatives to pdC1INH for
therapy because of ease of administration. However,
more experience is needed (see below). Ecallantide is
not currently recommended for selfadministration
because of the risk of anaphylactoid reactions.
2. Attack Treatment; infusion timing and regimen
Treatment is recommended as soon as the patient iden-
tifies symptoms, which, if untreated, are likely to
develop into a moderate or severe attack.
Comment:
Attack treatment with pdC1INH, rhC1INH, icatibant,
or ecallantide is likely to be most effective when given
early in the course of the attack [22]. Individualised ‘on
demand treatment’ during the initial or prodromal
stages of an attack enables patients to achieve almost
complete freedom from symptoms [24]. The dose of
pdC1INH treatment may be individually adjusted
depending on response. For airway events, the dose
should be 20 units/kg rounded up to the next highest
vial[18]. For treatment of other attacks, the best dosage
and timing of administration may differ from that
reported in randomised controlled studies which neces-
sarily evaluates fixed regimens in established attacks[18].
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Individual requirements may be evaluated by the patient,
with guidance from the physician. Many patients have
found doses lower than the licensed dose of 20 units/kg
pdC1INH effective, with doses of 500-1000 units suffi-
cing for many attacks[22,37,39,40]. A dose-finding trial
for home therapy with pdC1INH is needed.
3. Prophylaxis
Short term prophylaxis with pdC1INH is recom-
mended for high risk events. In patients with frequent
attacks this may include emotionally stressful events
such as exams, interviews, busy work periods and
major family events, as well as cover for medical and
dental procedures.
Long-term pdC1INH prophylaxis may be required, in
some cases, to control very frequent attacks.
Comment: pdC1INH is effective in short and long-
term prophylaxis. Controversy exists as to the relative
advantages of long-term prophylaxis compared with
treatment of early symptoms. PdC1INH (Cinryze™) is
licensed in the USA for long-term prophylaxis (1000
units twice weekly). Long-term prophylaxis reduces
attack frequency and severity, and improves quality of
life [14]. However, breakthrough attacks are frequent
and the total usage of pdC1INH is often increased
[14,26]. Although control may be improved by adjust-
ment of dose and frequency of treatments, many, but
not all, experts prefer early symptomatic treatment.
Icatibant, ecallantide and rhC1INH have short half-
lives and are therefore not recommended for prophy-
laxis at this time[20,21,41].
4. Route of administration
Recommendation: Most experts recommend venepunc-
ture with a small (e.g. 28G) butterfly needle infusion set
on each occasion that treatment with C1INH is
required.
Comment: Self-administration is associated with a low
incidence of cannulation failure and may preserve veins
more effectively than hospital-based care[26]. Indwelling
central line devices may be considered in exceptional
cases where venous access in a timely manner would
otherwise not be possible. However, the requirement for
treatment is lifelong and indwelling devices have a finite
life. Complications associated with indwelling venous
ports, particularly infection and occlusion, may be ser-
ious and are also likely to increase the frequency of
attacks. For these reasons, venous ports should be
avoided where possible. Icatibant given subcutaneously
may be considered where venous access is difficult.
5. Site of attack
Recommendation: Patients should be encouraged to
treat any attack at any site interfering with activities of
daily living or which is likely to be associated with
further disabling attacks.
(i) Laryngeal/upper airway attacks: Attacks affecting
head and neck should always be treated even if symp-
toms are mild because of the potential for rapid pro-
gression to laryngeal obstruction[2]. Patients are
strongly advised to seek emergency medical assistance
for all intraoral attacks and should home-administer
treatment while awaiting transfer to hospital.
(ii) Cutaneous attacks: Treatment with pdC1INH,
rhC1INH, icatibant or ecallantide is effective. Mild
attacks may not require treatment or may respond to
oral tranexamic acid[13]. Definitive treatment is recom-
mended for attacks that have potential to interfere with
daily activities.
(iii) Abdominal attacks: Treatment is likely to reduce
HAE-related disability and socioeconomic disadvantage.
Comment: With the exception of attacks affecting the
head and neck, which may progress to laryngeal
obstruction[2] symptoms are self limiting after 1-5 days
and patients may choose to leave these untreated or to
use symptomatic treatment.
6. Counselling/consent
Responsibilities of the doctor: We recommend that:
(i) The physician is responsible for carrying out an
assessment of the risks and benefits of home-administra-
tion. They should ensure that the patient and treatment
partner are able to provide fully informed consent, in
particular with respect to:
1. Blood product origin of pdC1INH
2. Appropriate treatment of attacks
3. Management of HAE-related emergencies
4. Management of treatment-associated side effects
(ii) The physician should ensure that a treatment plan
for 24 hour local emergency assistance and specialist
advice are available and that the patient and local hospi-
tal have written information.
(iii) The patient should be issued with appropriate
emergency treatment (at least one treatment dose
pdC1INH), as this is unlikely to be immediately available
in every medical facility.
(iv) The physician is responsible for ensuring that the
patient and partner are competent with the medical and
technical aspects of home administration. On-line
resources provide helpful support [for example: http://
www.haecanada.com]. These should not be a substitute
for direct access to advice from the specialist centre.
In practice, training may be delegated to a trained spe-
cialist nurse.
Responsibilities of the patient/treatment partner:
We recommend that:
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(i) The patient, with the support of the administration
partner, should be prepared to take responsibility for
the decision to treat, the technical aspects of safe use of
pdC1INH or other acute treatment and the safe disposal
of used equipment. Patients should keep an accurate
note of treatments and dates, including the lot numbers
of products used.
(ii) Patients should undertake to attend regular follow
up and refresher training, and to seek prompt assistance
from their emergency medical facility or from their phy-
sician or specialist nurse in the event of any query or
difficulty.
(iii) Patients should be aware of, and should accept,
the partial transfer from the physician of responsibility
for their medical care, and the wider responsibility to
the HAE community of ensuring that home administra-
tion is practised safely and effectively.
The patient should retain the option of returning to
hospital/clinic-based acute care at any time, or of leav-
ing the home-administration programme.
Written consent is advised.
7. Training programme
Recommendation: The training programme, which may
be led by an appropriately trained and experienced spe-
cialist nurse or physician, should be conducted over sev-
eral sessions to ensure that patient and treatment partner
have had sufficient practice to be familiar and confident
with technical and medical aspects of self-administration.
The patient should have received the proposed home
treatment for an attack on at least one occasion prior to
home therapy. Ideally, the patient/partner should treat an
attack under medical supervision, prior to home therapy.
However, in practice this may not always be possible.
When training is complete, there should be an assess-
ment to ensure that the patient and partner’s knowledge
and technical ability are sufficient.
Refresher training should be planned at regular inter-
vals, usually at least every 12 months.
Training should include:
Appropriate use of treatment product(s) (pdC1INH,
rhC1INH, icatibant)Management of emergencies, includ-
ing when to seek professional help.
Supply & storage of treatment productsHandwashing
and aseptic techniquePreparation of equipmentProduct
checking (dose/expiry date)Reconstitution of products if
neededIntravenous accessAdministration of medication,
including infusion rateDisposal of equipmentRecord
keeping (batch number, attack record)
8. Other HAE-like syndromes
(i) Acquired C1 inhibitor deficiency
Patients with acquired C1INH deficiency may also bene-
fit from home therapy. In some, but not all cases, higher
doses of C1INH may be required[26,42]. Icatibant is
likely to be an attractive option in this case [43].
(ii) HAE type 3
HAE type 3, although similar to other hereditary angioe-
demas, is not associated with C1INH deficiency [44-46].
This document does not consider HAE3, although if
effective acute treatments are identified, the same prin-
ciples will apply.
9. Emerging therapies
PdC1INH has the widest availability and licensure. Icati-
bant and ecallantide have variable licensure and
rhC1INH is applying for licensure. Availability of pro-
ducts will vary by jurisdiction.
Icatibant
Recommendation: Icatibant, where available, may be
considered as an alternative to C1INH for home
therapy.
Comment: Icatibant has the advantage of subcuta-
neous administration and, unlike C1INH, is supplied in
a prefilled syringe. Approximately 10% will need a sec-
ond dose of icatibant[20], and patients should hold a
backup dose.
By reducing the need for technical expertise, icatibant
has the potential to revolutionise the management of
HAE. However, it is not yet licensed for self-administra-
tion and experience is very limited. There is no experi-
ence of icatibant in children nor pregnant or lactating
women and for this reason, icatibant cannot currently
be recommended for these groups. Further information
from currently ongoing self-administration trial and
registry data will be vital in strengthening this
recommendation.
Ecallantide: As with icatibant, ecallantide is adminis-
tered by the subcutaneous route. Anaphylactic reactions
have been reported[47] and for this reason, the FDA has
mandated a registration program that requires an
informed consent that treatment with ecallantide only
be performed in the office of a physician experienced
and equipped to treat anaphylaxis. In light of this self-
treatment at home is not yet possible for ecallantide. At
the present time, due to lack of data, ecallantide is not
recommended in pregnant, nor lactating women, or
children under the age of 16 years.
Recombinant C1 inhibitor: Rhucin, a recombinant
C1INH, is currently in development. It is likely to be an
alternative to pdC1INH for the treatment of acute
attacks. It has a shorter half-life than pdC1INH, there-
fore its role in prophylaxis is uncertain[41].
Conclusion
Every patient with HAE should have the immediate
means to control an acute attack quickly and effectively,
in order to minimise impact on physical, social and
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economic wellbeing to themselves and their family.
Similar to the haemophilia home care model that has
worked so well for many years[35], the option of home
and self-administration offers the prospect of achieving
the aim of ‘each C1 inhibitor deficient (HAE) patient to
be able to manage his/her symptoms proactively in such
a way that they maintain personal safety and minimal
disruption in living a healthy and productive life’[32].
Appendix 1. Recommendations: summary
Inclusions
Home therapy training should be inclusive.
Extremes of age or lack of infusion partner are not
necessarily contraindications. Patients with HAE, with
acquired angioedema (acquired C1 inhibitor deficiency),
and, where treatment is available, HAE3, should be
included.
Prophylaxis, if required, should be optimised while
home therapy training is ongoing.
Attack Treatment
Attacks should be treated as early as possible.
Dose of C1 inhibitor should be individualised.
Prophylactic pdC1 inhibitor regimens may occasion-
ally be necessary.
Site of attack
Attacks at all sites may be self-treated at home. In the
case of laryngeal oedema, urgent transfer to hospital is
recommended after treatment.
Counselling/consent
Physician and patient should take joint and individual
responsibility for the safe and appropriate use of home
therapy.
Training programme
Should take part in a centre experienced in HAE
management.
Should offer ongoing support and refresher training.
Emerging therapies
pd C1 inhibitor home therapy programmes are well
established.
rC1 inhibitor is likely to offer an alternative for acute
treatment when licensed.
Icatibant offers great potential for expanding access to
treatment because of its ease of administration.
Ecallantide is not recommended for home therapy
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